TGF-β signaling: critical nexus of fibrogenesis and cancer

被引:40
作者
Giarratana, Anna O. [1 ]
Prendergast, Conor M. [2 ]
Salvatore, Mary M. [3 ]
Capaccione, Kathleen M. [3 ]
机构
[1] Northwell Hlth Pecon Bay Med Ctr, 1 Heroes Way, Riverhead, NY 11901 USA
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Columbia Univ, Dept Neurosci, New York, NY 11032 USA
关键词
TGF-beta; Cell signaling; Fibrosis; Cancer; Theranostics; Precision medicine; GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; BREAST-CANCER; PULMONARY-FIBROSIS; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL TRANSITION; PANCREATIC-CANCER; EPITHELIAL-CELLS; GLIOMA; PATHWAY;
D O I
10.1186/s12967-024-05411-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The transforming growth factor-beta (TGF-beta) signaling pathway is a vital regulator of cell proliferation, differentiation, apoptosis, and extracellular matrix production. It functions through canonical SMAD-mediated processes and noncanonical pathways involving MAPK cascades, PI3K/AKT, Rho-like GTPases, and NF-kappa B signaling. This intricate signaling system is finely tuned by interactions between canonical and noncanonical pathways and plays key roles in both physiologic and pathologic conditions including tissue homeostasis, fibrosis, and cancer progression. TGF-beta signaling is known to have paradoxical actions. Under normal physiologic conditions, TGF-beta signaling promotes cell quiescence and apoptosis, acting as a tumor suppressor. In contrast, in pathological states such as inflammation and cancer, it triggers processes that facilitate cancer progression and tissue remodeling, thus promoting tumor development and fibrosis. Here, we detail the role that TGF-beta plays in cancer and fibrosis and highlight the potential for future theranostics targeting this pathway.
引用
收藏
页数:16
相关论文
共 180 条
[91]   TGF-β/Smad and Renal Fibrosis [J].
Ma, Tao-Tao ;
Meng, Xiao-Ming .
RENAL FIBROSIS: MECHANISMS AND THERAPIES, 2019, 1165 :347-364
[92]   Luspatercept: First Approval [J].
Markham, Anthony .
DRUGS, 2020, 80 (01) :85-90
[93]   Smad transcription factors [J].
Massagué, J ;
Seoane, J ;
Wotton, D .
GENES & DEVELOPMENT, 2005, 19 (23) :2783-2810
[94]   TGFβ in cancer [J].
Massague, Joan .
CELL, 2008, 134 (02) :215-230
[95]   TGFβ signalling in context [J].
Massague, Joan .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2012, 13 (10) :616-630
[96]   EFFECTS OF TGF-BETA-1 (TRANSFORMING GROWTH-FACTOR-BETA-1) ON THE CELL-CYCLE REGULATION OF HUMAN BREAST ADENOCARCINOMA (MCF-7) CELLS [J].
MAZARS, P ;
BARBOULE, N ;
BALDIN, V ;
VIDAL, S ;
DUCOMMUN, B ;
VALETTE, A .
FEBS LETTERS, 1995, 362 (03) :295-300
[97]   Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes [J].
McGuigan, Andrew ;
Kelly, Paul ;
Turkington, Richard C. ;
Jones, Claire ;
Coleman, Helen G. ;
McCain, R. Stephen .
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (43) :4846-4861
[98]   Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery [J].
Mead, AL ;
Wong, TTL ;
Cordeiro, MF ;
Anderson, IK ;
Khaw, PT .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (08) :3394-3401
[99]   TGF-β: the master regulator of fibrosis [J].
Meng, Xiao-ming ;
Nikolic-Paterson, David J. ;
Lan, Hui Yao .
NATURE REVIEWS NEPHROLOGY, 2016, 12 (06) :325-338
[100]   Theragnostics before we found its name [J].
Modoni, Sergio ;
Frangos, Savvas ;
Iakovou, Ioannis ;
Boero, Michele ;
Mansi, Luigi .
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 65 (04) :299-305